immunologyTariff appliesAnnex III — Jul 31 2026

Stelara Tariff Rate & July 31, 2026 Deadline

Stelara (Ustekinumab) — manufactured by Johnson & Johnson in Netherlands. Treats psoriasis, crohn's disease. Typical US retail $12,500 per month.

Tariff breakdown

Applicable rate: 100% (Annex III)
Effective date: 2026-07-31 (98 days away)
Manufacturer: Johnson & Johnson
Country of origin: Netherlands
Annex III?: Yes
Current monthly retail: $12,500

Projected monthly retail, by pass-through scenario

Scenario	Pass-through	New monthly retail	Annual increase
Conservative	30%	$16,250	+$45,000
Likely	50%	$18,750	+$75,000
Worst case	100%	$25,000	+$150,000

Scenarios based on historical brand-pharma cost-shock pass-through. Not a forecast.

HTS classification

HTS 3002.15.0000

Ustekinumab monoclonal antibody, HTS 3002.15. Johnson & Johnson manufactures Stelara in the Netherlands — subject to the 100% tariff.

Source: USITC Harmonized Tariff Schedule, 2026 Revision 2 — hts.usitc.gov

Alternatives: generics, biosimilars & US-made options

Ustekinumab biosimilars (Wezlana, Selarsdi, Pyzchiva)

biosimilar

Multiple FDA-approved biosimilars launched in 2025. Biosimilars are exempt from the tariff.

Skyrizi (risankizumab, AbbVie)

therapeutic alternative

IL-23 inhibitor; Germany-made AbbVie product — tariff applies.

Always consult your prescriber before switching medications. Biosimilars and generics are not interchangeable in every state without physician approval.

FAQ: Stelara and the 2026 tariff

Will my Stelara prescription cost more after July 31, 2026?

Likely yes. Stelara is manufactured in Netherlands and is not exempt. Our conservative-case scenario assumes 30% pass-through (retail +$3,750/month), our likely-case 50% (+$6,250/month), and worst-case full pass-through (+$12,500/month).

Can I switch to a generic version of Ustekinumab?

No FDA-approved generic of Ustekinumab is widely available in the US as of 2026 Q2. Biosimilars or therapeutic alternatives (listed above) are the practical substitutes.

Is Stelara on the Medicare negotiated-price list?

Stelara is not among the first-round Medicare-negotiated drugs effective 2026. Check CMS announcements for subsequent negotiation rounds.

Importing pharmaceuticals commercially?

This page covers consumer drug pricing. For business imports (including finished-dose pharmaceuticals), use the full US import tariff calculator with HTS classification and Section 301/232/122 breakdown.

Disclaimer: Informational estimates based on public list prices, the April 2, 2026 Proclamation text, and USITC HTS data. Not medical, legal, or financial advice.

Talk to your doctor, pharmacist, and insurer about your specific medication.